UNIVEST FINANCIAL Corp Has $453,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

UNIVEST FINANCIAL Corp trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,573 shares of the medical research company’s stock after selling 54 shares during the period. UNIVEST FINANCIAL Corp’s holdings in Amgen were worth $453,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $4,589,900,000. Assenagon Asset Management S.A. increased its holdings in Amgen by 486.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 899,232 shares of the medical research company’s stock worth $258,997,000 after buying an additional 745,929 shares during the last quarter. abrdn plc raised its position in Amgen by 150.4% during the fourth quarter. abrdn plc now owns 1,043,609 shares of the medical research company’s stock worth $300,580,000 after acquiring an additional 626,810 shares in the last quarter. Los Angeles Capital Management LLC lifted its stake in Amgen by 111.9% in the fourth quarter. Los Angeles Capital Management LLC now owns 989,061 shares of the medical research company’s stock valued at $284,869,000 after acquiring an additional 522,367 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in Amgen by 11.4% in the third quarter. Royal Bank of Canada now owns 5,079,677 shares of the medical research company’s stock valued at $1,365,213,000 after buying an additional 518,689 shares during the period. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on AMGN shares. UBS Group increased their target price on shares of Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research report on Friday. Leerink Partnrs downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. TD Cowen lowered their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday. Finally, Morgan Stanley boosted their price target on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a report on Friday. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and a consensus target price of $305.05.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now owns 9,883 shares in the company, valued at $3,094,268.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.69% of the stock is currently owned by company insiders.

Amgen Price Performance

NASDAQ:AMGN traded up $0.82 during mid-day trading on Tuesday, hitting $300.30. 2,438,623 shares of the stock traded hands, compared to its average volume of 2,910,151. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. The company has a market cap of $161.07 billion, a PE ratio of 42.78, a price-to-earnings-growth ratio of 3.00 and a beta of 0.60. The business’s 50-day moving average price is $275.21 and its 200 day moving average price is $281.59.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The firm’s revenue was up 22.0% compared to the same quarter last year. During the same quarter last year, the business posted $3.98 earnings per share. On average, analysts expect that Amgen Inc. will post 19.46 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio is currently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.